You are here: Industry Insights > SARS-CoV-2

News List

NIHR, UKRI call for new COVID-19 research proposals pharmatimes
May 13, 2020
The NIHR and UK Research and Innovation (UKRI) are calling for new research proposals on the risk factors, transmission and prevalence of the COVID-19 virus SARS-CoV-2.
FDA Grants Hardy Diagnostics EUA for COVID-19 Rapid Antibody Test Kit americanpharmaceuticalreview
May 13, 2020
Hardy Diagnostics has received approval for a new in vitro diagnostic medical device: Anti-SARS-CoV-2 Rapid Test under the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA).
Viracor Eurofins Launches Antibody Tests for SARS-CoV-2 americanpharmaceuticalreview
May 13, 2020
Viracor Eurofins announced the launch of its antibody assays for Coronavirus (COVID-19) SARS-CoV-2.
Junshi, Lilly to Co-develop Antibody Therapies for COVID-19 contractpharma
May 13, 2020
Multiple neutralizing antibodies have been engineered, with the lead asset poised to enter clinical testing in the second quarter.
Sorrento, Mount Sinai to Develop COVI-Shield Antibody Therapy contractpharma
May 13, 2020
Sorrento Therapeutics Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-Shield) to potentially treat COVID-19.
OSE Immunotherapeutics Announces COVID-19 Prophylactic Vaccine Program americanpharmaceuticalreview
May 11, 2020
OSE Immunotherapeutics announced its team of immunologists is actively working on the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2.
Twist Bioscience identifies competitive antibodies for SARS-CoV-2 pharmaceutical-business-review
May 11, 2020
Twist Bioscience reported it has identified competitive antibodies to SARS-CoV-2, the virus that causes COVID-19, which could potentially be used for diagnostic tests or therapeutic treatments.
Tonix Pharmaceuticals licences three Covid-19 vaccine candidates pharmaceutical-technology
May 11, 2020
Tonix Pharmaceuticals has signed a research collaboration and exclusive licensing agreement with the University of Alberta in Canada for three new vaccine candidates to prevent Covid-19.
Vir, Alnylam to develop VIR-2703 RNAi therapeutic candidate for Covid-19 treatment pharmaceutical-business-review
May 08, 2020
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Lineage Cell Therapeutics to apply allogeneic dendritic cell therapy programme to Covid-19 vaccine d pharmaceutical-business-review
May 08, 2020
Lineage Cell Therapeutics, a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page